{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:53:59Z","timestamp":1781751239820,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04953-y","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:55:29Z","timestamp":1777614929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study"],"prefix":"10.1186","volume":"26","author":[{"given":"Katarzyna","family":"K\u0119pczy\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Domitrz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"St\u0119pie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Michalak-Siembida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Walczak\u2013Ciszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"8","key":"4953_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024241259591","volume":"44","author":"MF Prieto Peres","year":"2024","unstructured":"Prieto Peres MF, Sacco S, Pozo-Rosich P, et al. Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action. Cephalalgia. 2024;44(8):1\u20134. https:\/\/doi.org\/10.1177\/03331024241259591.","journal-title":"Cephalalgia"},{"key":"4953_CR2","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337\u201345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20.","journal-title":"Neurology"},{"key":"4953_CR3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337. https:\/\/doi.org\/10.1177\/0333102418759786.","journal-title":"Cephalalgia"},{"key":"4953_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-021-01371-3","volume":"23","author":"C Zecca","year":"2022","unstructured":"Zecca C, Ceschi A, Pinessi L, et al. Cost-effectiveness analysis of migraine prevention with anti-CGRP monoclonal antibodies: a systematic review. J Headache Pain. 2022;23:5. https:\/\/doi.org\/10.1186\/s10194-021-01371-3.","journal-title":"J Headache Pain"},{"key":"4953_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y.","journal-title":"J Headache Pain"},{"key":"4953_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24:56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"},{"key":"4953_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"4953_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20:92. https:\/\/doi.org\/10.1186\/s10194-019-1038-4.","journal-title":"J Headache Pain"},{"key":"4953_CR9","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/wnl.56.suppl_1.s20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20\u201328. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20.","journal-title":"Neurology"},{"key":"4953_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-018-0846-2","volume":"19","author":"TJ Steiner","year":"2018","unstructured":"Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17. https:\/\/doi.org\/10.1186\/s10194-018-0846-2.","journal-title":"J Headache Pain"},{"key":"4953_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3\u201320. https:\/\/doi.org\/10.1111\/head.12499.","journal-title":"Headache"},{"key":"4953_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/head.14804","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement. Headache. 2024;64:943\u201351. https:\/\/doi.org\/10.1111\/head.14804.","journal-title":"Headache"},{"key":"4953_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2024.0164","volume":"81","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich P, Dolezil D, Paemeleire K, et al. Early use of erenumab vs nonspecific oral migraine preventives: the APPRAISE randomized clinical trial. JAMA Neurol. 2024;81:461\u201371. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0164.","journal-title":"JAMA Neurol"},{"issue":"1","key":"4953_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s10194-024-01721-6","volume":"25","author":"L Grazzi","year":"2024","unstructured":"Grazzi L, Giossi R, Montisano DA, et al. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain. 2024;25(1):14. https:\/\/doi.org\/10.1186\/s10194-024-01721-6.","journal-title":"J Headache Pain"},{"key":"4953_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785\u201393. https:\/\/doi.org\/10.1016\/j.neuro.2005.01.017.","journal-title":"Neurotoxicology"},{"key":"4953_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015.","journal-title":"Physiol Rev"},{"key":"4953_CR17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s10194-024-01752-z","volume":"25","author":"C Novo Pereira","year":"2024","unstructured":"Novo Pereira C, Silva-N\u00e9to RP, Rodrigues MC, et al. Plasma CGRP levels in chronic migraine patients treated with onabotulinumtoxinA: a real-world study. J Headache Pain. 2024;25:45.","journal-title":"J Headache Pain"},{"key":"4953_CR18","doi-asserted-by":"publisher","first-page":"1417303","DOI":"10.3389\/fneur.2024.1417303","volume":"15","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Egeo G, Aurilia C, et al. Predictors of response to onabotulinumtoxinA in chronic migraine: a real-world study. Front Neurol. 2024;15:1417303. https:\/\/doi.org\/10.3389\/fneur.2024.1417303.","journal-title":"Front Neurol"},{"key":"4953_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19:115. https:\/\/doi.org\/10.1186\/s10194-018-0946-z.","journal-title":"J Headache Pain"},{"key":"4953_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-024-01789-4","volume":"25","author":"R Messina","year":"2024","unstructured":"Messina R, Huber FA, Puledda F, et al. Cost-effectiveness of early versus delayed access to anti-CGRP monoclonal antibodies in chronic migraine: a Markov model analysis. J Headache Pain. 2024;25:78. https:\/\/doi.org\/10.1186\/s10194-024-01789-4.","journal-title":"J Headache Pain"},{"key":"4953_CR21","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58:1408\u201326.","journal-title":"Headache"},{"key":"4953_CR22","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1111\/head.13407","volume":"18","author":"S Cargnin","year":"2018","unstructured":"Cargnin S, Viana M, Sances G, et al. Functional polymorphisms in COMT and SLC6A4 genes influence migraine disability and quality of life. Mol Med Rep. 2018;18:5518\u201326. https:\/\/doi.org\/10.1111\/head.13407.","journal-title":"Mol Med Rep"},{"key":"4953_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00265-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10:809\u201326. https:\/\/doi.org\/10.1007\/s40122-021-00265-x.","journal-title":"Pain Ther"},{"key":"4953_CR24","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"issue":"5","key":"4953_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28(5):484\u201395. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01555.x.","journal-title":"Cephalalgia"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04953-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04953-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04953-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:36:42Z","timestamp":1781750202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04953-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4953"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04953-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Bioethical Committee of the Medical University of Warsaw, Poland (approval number: AK-BE\/197\/2025; approval date: July 30, 2025). Given the retrospective nature of this study involving analysis of anonymized existing medical records, the ethics committee waived the requirement for informed consent in accordance with institutional guidelines for retrospective medical record reviews and applicable Polish data protection legislation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos). All data are presented in aggregate form without any identifying information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"394"}}